Top

Published in:

01-07-2019 | Optic Neuritis | Letter to the Editors

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation

Authors: Zoé L. E. van Kempen, Johannis A. van Rossum, Djoeke Doesburg, Iris Claessen, Annick de Vries, Anja ten Brinke, Bob W. van Oosten, Theo Rispens, Joep Killestein

Published in: Journal of Neurology | Issue 7/2019

Excerpt

Dear Sirs, …

Polman CH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910CrossRefPubMed

Calabresi PA et al (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69(14):1391–1403CrossRefPubMed

Oliver B et al (2011) Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler 17(3):368–371CrossRefPubMed

Sorensen PS et al (2011) Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 17(9):1074–1078CrossRefPubMed

Vennegoor A et al (2013) Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 19(5):593–600CrossRefPubMed

Rispens T et al (2011) Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem 411(2):271–276CrossRefPubMed

Debs R et al (2015) Extensive brain demyelinating lesions under natalizumab: the role of anti-natalizumab antibodies. Neurology 85(18):1630–1632CrossRefPubMed

Jensen PE et al (2012) Prediction of antibody persistency from antibody titres to natalizumab. Mult Scler 18(10):1493–1499CrossRefPubMed

Derfuss T et al (2017) alpha4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurol Neuroimmunol Neuroinflamm 4(5):e388CrossRefPubMedPubMedCentral

Title: Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation
Authors: Zoé L. E. van Kempen
Johannis A. van Rossum
Djoeke Doesburg
Iris Claessen
Annick de Vries
Anja ten Brinke
Bob W. van Oosten
Theo Rispens
Joep Killestein
Publication date: 01-07-2019
Publisher: Springer Berlin Heidelberg
Keywords: Optic Neuritis
Natalizumab
Published in: Journal of Neurology / Issue 7/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09327-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2019

Financial capacity in frontotemporal dementia and related presentations

Gluten sensitivity and epilepsy: a systematic review

Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson’s disease

In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients

Classification of degenerative parkinsonism subtypes by support-vector-machine analysis and striatal 123I-FP-CIT indices

“Can’t seem to keep my mind to it”: did Arthur Miller’s Salesman have dementia with Lewy bodies?